#BCL2i
LightNews LightNews
peerview.bsky.social
🔍 What challenges do you face when treating #MDS, #MF, or #CLL? 🔍
Our expert panels will share real-world case discussions and insights on individualizing treatment. From innovative JAKi in MF to BTKi-BCL2i combinations in CLL, these programs will elevate your practice.
💼 HealthTree Foundation
November 25, 2024 at 2:43 PM
rarediseaseadvisor.bsky.social
Patients with chronic lymphocytic leukemia (#CLL) who discontinued covalent #BTKi and later required #BCL2i therapy faced diminishing clinical benefit, underscoring a pressing therapeutic gap.

Read here: https://bit.ly/3YkhbQn

#RareDisease #ChronicLymphocyticLeukemia #MedSky
Prognosis Worsens Once Patients Exhaust BTKi and BCL2i in CLL
Most patients with CLL who discontinued BTK inhibitors and later received BCL2i achieved early responses but poor long-term outcomes.
bit.ly
December 15, 2025 at 6:42 PM
majorajay.bsky.social
Time-limited zanu+ven R/R CLL @inhyeahn #ASH24:
ORR in 3 cohorts:
- BTKi/BCL2i naive: 91%
- BTKi/BCL2i exposed & stopped other than PD: 100%
- PD on cBTKi w/o C481mut: 100%
AEs: 42% G1-2 diarrhea, 8% afib, no TLS
Great fixed-duration R/R option. Look out for MRD data. #leusm
November 29, 2024 at 3:57 PM
hematologyadvisor.bsky.social
Patients with chronic #lymphocyticLeukemia who discontinued covalent BTKi and later required BCL2i therapy faced diminishing clinical benefit, underscoring a pressing therapeutic gap. From @rarediseaseadvisor.bsky.social.

https://bit.ly/3MX8zg6

#CLL #leusm
Prognosis Worsens Once Patients Exhaust BTKi and BCL2i in CLL
Longitudinal data reveal consistent initial responsiveness to targeted agents but limited durability once patients cycle through both BTKi and BCL2i classes.
bit.ly
December 25, 2025 at 3:55 PM
rhrleblanc.bsky.social
To my fellow colleagues hematologists, flip floping is not unique to politics :-(

To BTKied in induction, or to not BTKied...
To ASCT or not to ASCT
To maintain or not to maintain

ashpublications.org/blood/articl...

How many combinations of MoAbs-R2-BTKi-BCL2i can you study without getting dizzy?
Introduction to a review series on mantle cell lymphoma: sands shifting in the darkness
Mantle cell lymphoma (MCL) is a rare and aggressive form of non-Hodgkin B-cell lymphoma that defies cures in most patients. Over the last decade, significa
ashpublications.org
March 12, 2025 at 2:40 AM